Analysts expect MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) to post sales of $9.00 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for MaxCyte’s earnings, with estimates ranging from $8.90 million to $9.10 million. MaxCyte reported sales of $7.11 million in the same quarter last year, which would suggest […]
OncoCyte (NYSEAMERICAN:OCX – Get Rating) had its price objective reduced by equities research analysts at Piper Sandler from $1.80 to $1.40 in a research report issued on Sunday, The Fly reports. Piper Sandler’s price objective suggests a potential upside of 23.89% from the company’s current price. Several other equities analysts also recently weighed in on […]
Bioqual (OTCMKTS:BIOQ – Get Rating) and MaxCyte (NASDAQ:MXCT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Valuation & Earnings This table compares Bioqual and MaxCyte’s gross revenue, […]
Shares of OncoCyte Co. (NYSEAMERICAN:OCX – Get Rating) have earned an average rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among brokers […]
Equities analysts predict that MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) will announce earnings of ($0.07) per share for the current quarter, Zacks reports. Two analysts have issued estimates for MaxCyte’s earnings. The firm is expected to report its next quarterly earnings results on Monday, January 1st. According to Zacks, analysts expect that MaxCyte will report […]